Wang J, Waxman J
Department of Oncology, Hammersmith Hospital, Imperial College of Medicine, Du Cane Rd., London W12 ONN, London, United Kingdom
Urol Oncol. 2000 Apr 1;5(3):93-96. doi: 10.1016/s1078-1439(99)00054-x.
The development of chemotherapy for prostate cancer has been limited by the toxicity of treatment in an elderly population. The evaluation of newer agents in the 1990's has allowed chemotherapy to be given which has fewer side effects, and has improved life quality. The investigation of adjuvant treatment may be warranted in an attempt to improve the outlook of this condition.
